片仔癀(600436.SH):同意在研究院下設成立新部門-科技情報中心
格隆匯 11 月 25日丨片仔癀(600436.SH)公佈,公司第六屆董事會第三十三次會議決議,審議通過《公司關於成立科技情報中心的議案》;
為順應醫藥產業創新發展趨勢,建立科學的醫藥科技情報及知識產權管理體系,強化科研項目知識產權創造、運用、保護和管理,同意公司在研究院下設成立新部門-科技情報中心。科技情報中心的主要職責如下:負責蒐集、篩選醫藥研發相關的國家法律法規、方針政策的動態信息,編制信息快報;負責發明專利和實用新型專利的管理;負責課題科技查新、醫藥文獻數據庫的管理等工作。
該議案無需提交至公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.